Rapid drug desensitisation
Inducing temporary tolerance to an essential culprit drug · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Rapid drug desensitisation delivers incrementally increasing doses of a culprit drug over hours to induce temporary tolerance when there is no acceptable alternative, as with chemotherapy, antibiotics or aspirin. It is a specialist, monitored procedure that does not cure allergy and must be repeated for each treatment course.
Red flags
- History of SJS/TEN, DRESS or AGEP (absolute contraindication)
- Haemodynamic instability during the protocol
- Breakthrough anaphylaxis not controlled by pausing and treating
- Organ-specific severe reactions (hepatitis, nephritis)
- Lapse in dosing requiring restart
Assessment
Differential diagnosis
- True IgE-mediated allergy (suitable for desensitisation)
- Severe delayed T-cell reaction (SJS/TEN/DRESS — contraindication)
- Non-immune intolerance / side effect
- Infusion-rate reaction (may only need slower rate)
- Anxiety or vasovagal reaction
Investigations
- Confirm the reaction phenotype and exclude severe cutaneous adverse reactions
- Skin testing / specific IgE to the culprit where available
- Baseline and post-reaction mast cell tryptase
- Confirm there is no safe alternative drug
- Baseline observations and continuous monitoring during the protocol
Management
- Exclude absolute contraindications (SJS/TEN, DRESS, severe organ-specific reactions)
- Obtain informed consent and perform in a monitored setting with resuscitation facilities
- Give premedication (antihistamine and corticosteroid) per protocol
- Prepare serial dilutions and administer stepwise increasing doses at fixed intervals (e.g. 12-16 steps over 4-8 h)
- Monitor continuously; for breakthrough reactions pause, treat, then resume at a lower step
- Reach the full therapeutic dose and administer the treatment
- Maintain continuous dosing thereafter — a lapse loses tolerance and the protocol must be repeated
- Document the protocol and plan repeat desensitisation for each future course
Drugs & doses
Chlorphenamine — 10 mg IV/IM as premedication and for breakthrough reactions
Hydrocortisone — 100-200 mg IV as premedication
Adrenaline IM — 500 mcg (0.5 mL 1:1000) for breakthrough anaphylaxis
Montelukast — 10 mg orally as adjunct premedication in some protocols
Salbutamol — 5 mg nebulised for breakthrough bronchospasm
Disposition
Perform as an inpatient/day-case specialist procedure with monitoring; continue the drug uninterrupted and repeat desensitisation for each course.
Complications & pitfalls
- Breakthrough anaphylaxis during escalation
- Loss of tolerance if dosing is interrupted
- Failure of desensitisation requiring alternative therapy
- Delay to essential treatment
- Procedure-related anxiety
Exam pearls
- Desensitisation induces temporary tolerance only — it does not remove the allergy label permanently
- Severe delayed reactions (SJS/TEN/DRESS) are absolute contraindications
- Continuous, uninterrupted dosing is essential to maintain tolerance
- Always perform in a monitored setting with immediate access to adrenaline
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.